Principal Financial Group Inc. Lowers Stock Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Principal Financial Group Inc. reduced its position in Fulgent Genetics, Inc. (NASDAQ:FLGTFree Report) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 113,842 shares of the company’s stock after selling 2,431 shares during the quarter. Principal Financial Group Inc. owned approximately 0.38% of Fulgent Genetics worth $3,291,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its stake in Fulgent Genetics by 11.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,447,153 shares of the company’s stock worth $41,839,000 after buying an additional 147,505 shares during the period. Invesco Ltd. increased its position in shares of Fulgent Genetics by 150.3% during the third quarter. Invesco Ltd. now owns 312,627 shares of the company’s stock worth $8,360,000 after acquiring an additional 187,717 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Fulgent Genetics by 14.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 267,313 shares of the company’s stock valued at $7,728,000 after purchasing an additional 33,141 shares during the period. Brandywine Global Investment Management LLC acquired a new position in Fulgent Genetics during the 3rd quarter worth $2,430,000. Finally, Victory Capital Management Inc. increased its holdings in Fulgent Genetics by 31.3% during the 3rd quarter. Victory Capital Management Inc. now owns 71,810 shares of the company’s stock worth $1,920,000 after purchasing an additional 17,103 shares during the period. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Piper Sandler decreased their price objective on Fulgent Genetics from $28.00 to $25.00 and set a “neutral” rating for the company in a research note on Wednesday, March 6th.

Check Out Our Latest Report on FLGT

Fulgent Genetics Trading Down 3.3 %

Shares of FLGT stock opened at $20.65 on Friday. The company has a market cap of $617.85 million, a P/E ratio of -3.71 and a beta of 1.43. The firm has a fifty day moving average price of $21.25 and a 200 day moving average price of $24.47. Fulgent Genetics, Inc. has a 12 month low of $19.88 and a 12 month high of $44.09.

Fulgent Genetics (NASDAQ:FLGTGet Free Report) last released its quarterly earnings data on Friday, May 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.20. Fulgent Genetics had a negative return on equity of 2.92% and a negative net margin of 57.72%. The business had revenue of $64.49 million during the quarter, compared to analysts’ expectations of $65.74 million. On average, equities analysts forecast that Fulgent Genetics, Inc. will post -2.12 EPS for the current year.

Fulgent Genetics Company Profile

(Free Report)

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.

Featured Articles

Institutional Ownership by Quarter for Fulgent Genetics (NASDAQ:FLGT)

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.